Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3710206 | 1.00 | GRM5 (0.45) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3719860 | 0.90 | GRM5 (0.47) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3775701 | 0.90 | GRM5 (0.47) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3713971 | 0.88 | GRM5 (0.45) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3771322 | 0.88 | GRM5 (0.45) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3711478 | 0.88 | GRM5 (0.47) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3773523 | 0.88 | GRM5 (0.47) | GRM5CYP3A4FBP1MAPTMAPK1 | |
| SCHEMBL3775736 | 0.88 | GRM5 (0.49) | GRM5CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL3720958 | 0.88 | GRM5 (0.49) | GRM5CYP3A4MAPTMAPK1ALDH1A1 | |
| SCHEMBL3721188 | 0.87 | GRM5 (0.44) | GRM5CYP3A4FBP1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | claimed |
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | GRM5 1/4885CYP3A4 3028/4885FBP1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.